NASDAQ · Medical - Diagnostics & Research

Illumina, Inc. (ILMN) Stock

$269.42 +0.01% NASDAQ: ILMN Healthcare

Valuation

MetricValue
Price$269.42
Market Cap$40.68B
P/E Ratio49.91
P/B Ratio14.37
P/S Ratio9.09
EPS (TTM)$5.44
52-Week High$307.08
52-Week Low$88.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE31.08%
ROA12.41%
ROCE18.57%
Gross Margin68.29%
Operating Margin18.33%
Net Margin18.36%
Debt/Equity0.89
Current Ratio1.75

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.5B$4.6B$4.5B$4.4B$4.3B
Operating Profit$-123.0M$-4.2B$-1.1B$-833.0M$864.0M
Net Profit$762.0M$-4.4B$-1.2B$-1.2B$850.0M
EPS$5.05$-28.05$-7.35$-7.69$5.45
Op Margin-2.7%-91.2%-23.7%-19.1%19.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$15.2B$12.3B$10.1B$6.3B$6.6B
Total Liabilities$4.5B$5.7B$4.4B$3.9B$3.9B
Cash$1.2B$2.0B$1.0B$1.1B$1.4B
Borrowings$2.5B$3.6B$2.3B$2.6B$2.6B

Latest News

Element Biosciences Prevails in German Patent Case Against Illumina Business Wire · Jul 14, 2026 Alamar Hits A High Note On Alzheimer's Buzz Trefis · Jul 13, 2026 Cathie Wood Loads Up on SpaceX, Meta, Eli Lilly and Circle Group GuruFocus.com · Jul 13, 2026 Jeff Bezos Backed Grail Before It Lost Half Its Value. Here's Whether He Was Early -- or Just Wrong. Motley Fool · Jul 13, 2026 Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN Zacks · Jul 10, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$545.0M$392.0M$478.0M$837.0M$1.1B
Investing Cash Flow$-1.3B$-877.0M$-426.0M$-306.0M$-203.0M
Financing Cash Flow$-582.0M$-54.0M$-42.0M$-1.1B$-783.0M
Net Cash Flow$-578.0M$779.0M$-963.0M$79.0M$291.0M
Free Cash Flow$337.0M$106.0M$282.0M$709.0M$931.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-1.57
EV / EBITDA31.06
FCF Yield2.30%
Quick Ratio1.40
Interest Coverage12.56
Return 1Y167.16%
Return 3Y136.48%
Return 5Y-34.69%

Ownership

Insiders Held0.20%
Institutions Held106.37%
Institutions Float Held106.58%
Institutional HolderSharesReport Date
Blackrock Inc.19,023,5902026-03-31
Capital World Investors15,549,9602026-03-31
Vanguard Portfolio Management LLC6,823,6542026-03-31
Vanguard Capital Management LLC6,594,8362026-03-31
State Street Corporation6,429,3442026-03-31

About Illumina, Inc.

Illumina, Inc. is led by CEO Jacob Thaysen, employs 8,970 people, headquartered in San Diego, US, publicly traded since 2000.

Illumina, Inc. (ILMN) stock trades at $269.42 with a market capitalization of $40.68B. The stock is valued at a price-to-earnings (P/E) ratio of 49.91, price-to-book of 14.37, price-to-sales of 9.09. Over the past 52 weeks the stock has ranged between $88.00 and $307.08, and currently trades 12.3% below its 52-week high.

On profitability, Illumina, Inc. generates a return on equity (ROE) of 31.08%, above the typical market range of roughly 12-15%, return on capital employed of 18.57%, an operating margin of 18.33%, a net profit margin of 18.36%.

In its most recent fiscal year, Illumina, Inc. reported annual revenue of $4.3B, net profit of $850.0M. Over the last 5 fiscal years, revenue grew at an average annual rate of 6.0%, and net profit grew at an average annual rate of 5.3%.

The balance sheet shows a debt-to-equity ratio of 0.89, a current ratio of 1.75, total assets of $6.6B, $1.4B in cash and equivalents.

ILMN has an average daily trading volume of 2,524,117 shares, a beta of 1.47 (historically more volatile than the overall market).

Illumina, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Illumina, Inc. reported revenue of $2.4B rising to $4.3B, a change of +80.9% across 10 years. Compounded, revenue has grown 6.0% a year over five years, -1.8% over three, -0.8% over the last twelve months. Net profit rose to $850.0M.

Operating margin went from 24.5% in 2016 to 19.9% in 2025, a fall of 4.5 percentage points. The most recent net margin is 18.36%. On a trailing twelve-month basis to Jun '26, revenue is $4.5B and net profit $825.0M.

Borrowings rose from $1.0B to $2.6B, cash from operations was $1.1B in the latest year, positive in 10 of the last 10.

Return on equity has averaged -20.0% over five years, and was 31.2% in the most recent year.

The share price itself has compounded at -16.7% a year over five years, -10.4% over three, 78.6% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Illumina, Inc. (ILMN) — frequently asked questions

What is Illumina, Inc. (ILMN) stock price today?

Illumina, Inc. (ILMN) is currently trading at $269.42, up 0.01% today.

What is ILMN P/E ratio?

Illumina, Inc.'s P/E ratio is 49.91. This is above the typical market average of roughly 18-22x. A high P/E often reflects higher expected earnings growth, a temporary dip in earnings, or both.

What is ILMN return on equity (ROE)?

Illumina, Inc.'s return on equity (ROE) is 31.08%. ROE measures net income relative to shareholders' equity. This is above the typical market range of roughly 12-15%.

What is Illumina, Inc.'s market cap?

Illumina, Inc. has a market capitalization of $40.68B.

Does ILMN pay a dividend?

Illumina, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does ILMN carry?

Illumina, Inc. has a debt-to-equity ratio of 0.89. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is ILMN's profit margin?

Illumina, Inc. reports a net profit margin of 18.36% — the share of revenue left after every cost, including tax and interest.

What sector is ILMN in?

Illumina, Inc. is classified under Healthcare, in the Medical - Diagnostics & Research industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is ILMN listed on?

Illumina, Inc. trades on NASDAQ under the ticker ILMN.

What is ILMN's 52-week range?

Over the last year Illumina, Inc. has traded between $88.00 and $307.08.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens ILMN currently matches

On the figures above, Illumina, Inc. passes the filters for 8 of our ready-made screens, among them High ROE Stocks, Quality Stocks, High ROA Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

High ROE StocksQuality StocksHigh ROA StocksCompanies With Highest ROELarge Cap StocksHealthcare Stocks To BuyHigh Gross Margin StocksDebt to Equity Below 1 Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.